Risk of fractures with glitazones: A critical review of the evidence to date

Drug Safety

Volumn 32, Issue 7, 2009, Pages 539-547

  Bodmer, Michael ^a   Meier, Christian ^a   Kraenzlin, Marius E ^a   Meier, Christoph R ^a,b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; GLIBENCLAMIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PARATHYROID HORMONE[1-34]; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; VITAMIN D;

BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; DRUG EFFECT; FRACTURE; HUMAN; MESENCHYMAL STEM CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK FACTOR;

ANIMALS; BONE DENSITY; DIABETES MELLITUS, TYPE 2; FEMALE; FRACTURES, BONE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PPAR GAMMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SEX FACTORS; THIAZOLIDINEDIONES;

EID: 67649298019     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/00002018-200932070-00001     Document Type: Review

References (74)

1. Yki-Jarvinen H. The PROactive study: some answers, many questions. Lancet 2005 Oct 8; 366 (9493): 1241-2
2. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006 Sep 23; 368 (9541): 1096-105
3. Stout DL, Fugate SE. Thiazolidinediones for treatment of polycystic ovary syndrome. Pharmacotherapy 2005 Feb; 25 (2): 244-52
4. Solomon CG. The epidemiology of polycystic ovary syndrome: prevalence and associated disease risks. Endocrinol Metab Clin North Am 1999 Jun; 28 (2): 247-63
5. Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) trial. Gastroenterology 2008 Jul; 135 (1): 100-10
6. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004 Sep 9; 351 (11): 1106-18
7. Miyazaki Y, Defronzo RA. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes Metab 2008 Dec; 10 (12): 1204-11
8. Betteridge DJ. Effects of pioglitazone on lipid and lipoprotein metabolism. Diabetes Obes Metab 2007 Sep; 9 (5): 640-7
9. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006 Dec 7; 355 (23): 2427-43 10. Rosenstock J, Chou H, Matthaei S, et al. Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes. Diabetes Obes Metab 2008 Sep; 10 (10): 862-73 11. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007 Jun 14; 356 (24): 2457-71 12. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007 Sep 12; 298 (10): 1189-95 13. Singh S, Loke YK. The safety of rosiglitazone in the treatment of type 2 diabetes. Expert Opin Drug Saf 2008 Sep; 7 (5): 579-85 14. Stafylas PC, Sarafidis PA, Lasaridis AN. The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality. Int J Cardiol 2009 Jan 24; 131 (3): 298-304 15. Monami M, Marchionni N, Mannucci E. Winners and losers at the rosiglitazone gamble: a meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone. Diabetes Res Clin Pract 2008 Oct; 82 (1): 48-57 16. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007 Sep 12; 298 (10): 1180-8 17. Khanderia U, Pop-Busui R, Eagle KA. Thiazolidinediones in type 2 diabetes: a cardiology perspective. Ann Pharmacother 2008 Oct; 42 (10): 1466-74 18. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008 Apr 2; 299 (13): 1561-73 19. Abbasi F, Farin HM, Lamendola C, et al. Pioglitazone administration decreases cardiovascular disease risk factors in insulin-resistant smokers. Metabolism 2008 Aug; 57 (8): 1108-14 20. Charbonnel B, Dormandy J, Erdmann E, et al. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004 Jul; 27 (7): 1647-53 21. Short R. Fracture risk is a class effect of glitazones. BMJ 2007 Mar 17; 334 (7593): 551 22. Hampton T. Diabetes drugs tied to fractures in women. JAMA 2007 Apr 18; 297 (15): 1645 23. Grey A. Thiazolidinedione-induced skeletal fragility: mechanisms and implications. Diabetes Obes Metab 2009 Apr; 11 (4): 275-84
10. Yki-Jarvinen H. The PROactive study: some answers, many questions. Lancet 2005 Oct 8; 366 (9493): 1241-2
11. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006 Sep 23; 368 (9541): 1096-105
12. Stout DL, Fugate SE. Thiazolidinediones for treatment of polycystic ovary syndrome. Pharmacotherapy 2005 Feb; 25 (2): 244-52
13. Solomon CG. The epidemiology of polycystic ovary syndrome: prevalence and associated disease risks. Endocrinol Metab Clin North Am 1999 Jun; 28 (2): 247-63
14. Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) trial. Gastroenterology 2008 Jul; 135 (1): 100-10
15. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004 Sep 9; 351 (11): 1106-18
16. Miyazaki Y, Defronzo RA. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes Metab 2008 Dec; 10 (12): 1204-11
17. Betteridge DJ. Effects of pioglitazone on lipid and lipoprotein metabolism. Diabetes Obes Metab 2007 Sep; 9 (5): 640-7
18. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006 Dec 7; 355 (23): 2427-43
19. Rosenstock J, Chou H, Matthaei S, et al. Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes. Diabetes Obes Metab 2008 Sep; 10 (10): 862-73
20. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007 Jun 14; 356 (24): 2457-71
21. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007 Sep 12; 298 (10): 1189-95
22. Singh S, Loke YK. The safety of rosiglitazone in the treatment of type 2 diabetes. Expert Opin Drug Saf 2008 Sep; 7 (5): 579-85
23. Stafylas PC, Sarafidis PA, Lasaridis AN. The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality. Int J Cardiol 2009 Jan 24; 131 (3): 298-304
24. Monami M, Marchionni N, Mannucci E. Winners and losers at the rosiglitazone gamble: a meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone. Diabetes Res Clin Pract 2008 Oct; 82 (1): 48-57
25. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007 Sep 12; 298 (10): 1180-8
26. Khanderia U, Pop-Busui R, Eagle KA. Thiazolidinediones in type 2 diabetes: a cardiology perspective. Ann Pharmacother 2008 Oct; 42 (10): 1466-74
27. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008 Apr 2; 299 (13): 1561-73
28. Abbasi F, Farin HM, Lamendola C, et al. Pioglitazone administration decreases cardiovascular disease risk factors in insulin-resistant smokers. Metabolism 2008 Aug; 57 (8): 1108-14
29. Charbonnel B, Dormandy J, Erdmann E, et al. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004 Jul; 27 (7): 1647-53
30. Short R. Fracture risk is a class effect of glitazones. BMJ 2007 Mar 17; 334 (7593): 551
31. Hampton T. Diabetes drugs tied to fractures in women. JAMA 2007 Apr 18; 297 (15): 1645
32. a 2009 Adis Data Information BV. All rights reserved. Drug Safety 2009; 32 (7)
33. Giaginis C, Tsantili-Kakoulidou A, Theocharis S. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism. Fundam Clin Pharmacol 2007 Jun; 21 (3): 231-44
34. Gimble JM, Robinson CE, Wu X, et al. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol 1996 Nov; 50 (5): 1087-94
35. Kawaguchi H, Akune T, Yamaguchi M, et al. Distinct effects of PPARgamma insufficiency on bonemarrow cells, osteoblasts, and osteoclastic cells. J Bone Miner Metab 2005; 23 (4): 275-9
36. Lecka-Czernik B, Moerman EJ, Grant DF, et al. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002 Jun; 143 (6): 2376-84
37. Okazaki R, Toriumi M, Fukumoto S, et al. Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 1999 Nov; 140 (11): 5060-5
38. Mbalaviele G, Abu-Amer Y, Meng A, et al. Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation. J Biol Chem 2000 May 12; 275 (19): 14388-93
39. Chan BY, Gartland A, Wilson PJ, et al. PPAR agonists modulate human osteoclast formation and activity in vitro. Bone 2007 Jan; 40 (1): 149-59
40. Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 2008 Feb; 19 (2): 129-37
41. Rosen CJ, Bouxsein ML. Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2006 Jan; 2 (1): 35-43
42. Lazarenko OP, Rzonca SO, Hogue WR, et al. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 2007 Jun; 148 (6): 2669-80
43. Wan Y, Chong LW, Evans RM. PPAR-gamma regulates osteoclastogenesis in mice. Nat Med 2007 Dec; 13 (12): 1496-503
44. Sottile V, Seuwen K, Kneissel M. Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int 2004 Oct; 75 (4): 329-37
45. Akune T, Ohba S, Kamekura S, et al. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004 Mar; 113 (6): 846-55
46. Klein RF, Allard J, Avnur Z, et al. Regulation of bone mass in mice by the lipoxygenase gene Alox15. Science 2004 Jan 9; 303 (5655): 229-32
47. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006 Sep; 91 (9): 3349-54
48. Glintborg D, Andersen M, Hagen C, et al. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 2008 May; 93 (5): 1696-701
49. Okazaki R, Miura M, Toriumi M, et al. Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocr J 1999 Dec; 46 (6): 795-801
50. Berberoglu Z, Gursoy A, Bayraktar N, et al. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 2007 Sep; 92 (9): 3523-30
51. Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated eceptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007 Apr; 92 (4): 1305-10
52. Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008 Apr 28; 168 (8): 820-5
53. Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 2007 Jun; 30 (6): 1574-6
54. Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazoneassociated fractures in type 2 diabetes: an Analysis from a Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008 May; 31 (5): 845-51
55. US Food and Drug Administration. Actos (pioglitazone) tablets [online]. Available from URL: http://www.fda.gov/ medwatch/safety/2007/safety07.htm#actos [Accessed 2009 Apr 29]
56. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a metaanalysis. CMAJ 2009 Jan 6; 180 (1): 32-9
57. Sanders KM, Seeman E, Ugoni AM, et al. Age- and genderspecific rate of fractures in Australia: a population-based study. Osteoporos Int 1999; 10 (3): 240-7
58. Garraway WM, Stauffer RN, Kurland LT, et al. Limb fractures in a defined population: I. Frequency and distribution. Mayo Clin Proc 1979 Nov; 54 (11): 701-7
59. Nicodemus KK, Folsom AR. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 2001 Jul; 24 (7): 1192-7
60. Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 2001 Jan; 86 (1): 32-8
61. Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 2006 Sep; 91 (9): 3404-10
62. Strotmeyer ES, Cauley JA, Schwartz AV, et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med 2005 Jul 25; 165 (14): 1612-7
63. Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 2005 Jul; 48 (7): 1292-9
64. Ahmed LA, Joakimsen RM, Berntsen GK, et al. Diabetes mellitus and the risk of non-vertebral fractures: the Tromso study. Osteoporos Int 2006; 17 (4): 495-500
65. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR, on behalf of the PROactive investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf 2009; 32 (3): 187-202
66. Verhaeghe J, Suiker AM, Einhorn TA, et al. Brittle bones in spontaneously diabetic female rats cannot be predicted by bone mineral measurements: studies in diabetic and ovariectomized rats. J Bone Miner Res 1994 Oct; 9 (10): 1657-67
67. Schwartz AV, Hillier TA, Sellmeyer DE, et al. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care 2002 Oct; 25 (10): 1749-54
68. Gregg EW, Mangione CM, Cauley JA, et al. Diabetes and incidence of functional disability in older women. Diabetes Care 2002 Jan; 25 (1): 61-7
69. Cundy TF, Edmonds ME, Watkins PJ. Osteopenia and metatarsal fractures in diabetic neuropathy. Diabet Med 1985 Nov; 2 (6): 461-4
70. Schwartz AV, Sellmeyer DE, Strotmeyer ES, et al. Diabetes and bone loss at the hip in older black and white adults. J Bone Miner Res 2005 Apr; 20 (4): 596-603
71. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006 Aug; 29 (8): 1963-72
72. Edwards KL, Alvarez C, Irons BK, et al. Third-line agent selection for patients with type 2 diabetes mellitus uncontrolled with sulfonylureas and metformin. Pharmacotherapy 2008 Apr; 28 (4): 506-21
73. Massi-Benedetti M, Orsini-Federici M. Treatment of type 2 diabetes with combined therapy: what are the pros and cons? Diabetes Care 2008 Feb; 31 Suppl. 2: S131-5
74. Ton FN, Gunawardene SC, Lee H, et al. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 2005 Mar; 20 (3): 464-70